Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Hiroki, Osumi"'
Autor:
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract “NeoRAS WT” refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequen
Externí odkaz:
https://doaj.org/article/32159db2ff3a4f6f8eaee8f39adf3f96
Autor:
Koshiro Fukuda, Hiroki Osumi, Koichiro Yoshino, Izuma Nakayama, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic
Externí odkaz:
https://doaj.org/article/d13b8dce74d849dab9090169595d05c9
Autor:
Hiroki Osumi, Atsuo Takashima, Akira Ooki, Yuri Yoshinari, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Natsuko Okita, Ryoichi Sawada, Kota Ouchi, Koshiro Fukuda, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
Translational Oncology, Vol 35, Iss , Pp 101718- (2023)
Purpose: As circulating tumor DNA (ctDNA) measurement becomes more widespread, the “NeoRAS” phenomenon, where tissue rat sarcoma viral oncogene homolog (RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorec
Externí odkaz:
https://doaj.org/article/2dd4356f4b714e61ada692c8cdb096f1
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a predominant histological subtype of EC that has unique etiology, molecular profiles, and clinico
Externí odkaz:
https://doaj.org/article/d4de0e4eddee466e86091481d9000fc4
Autor:
Hiroki Osumi, Eiji Shinozaki, Akira Ooki, Keitaro Shimozaki, Daisaku Kamiimabeppu, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Abstract Background Circulating tumor DNA (ctDNA) is a biomarker with potential to reflect comprehensive genomic information and overcome intratumor heterogeneity. In contrast, carcinoembryonic antigen (CEA) is a conventional tumor marker for predict
Externí odkaz:
https://doaj.org/article/c9f12771a9cf45ee8c0b5883f30ac9bb
Autor:
Atsuo Takashima, Ken Kato, Eiji Shinozaki, Kensei Yamaguchi, Takeru Wakatsuki, Hiroki Osumi, Naoki Ishizuka, Kota Ouchi, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Boku Narikazu
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Introduction A new concept of ‘NeoRAS wild-type (WT)’, which means conversion of RAS status from RAS mutant to RAS WT after treatment, has been reported. Previous observational and proof-of-concept studies have demonstrated the efficacy of epider
Externí odkaz:
https://doaj.org/article/2594d3e5f4254f72b4e2a4d2cd0fb3c3
Autor:
Yoshitaka Tokai, Junko Fujisaki, Naoki Ishizuka, Hiroki Osumi, Ken Namikawa, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Kazumasa Miki, Tomohiro Tsuchida
Publikováno v:
JGH Open, Vol 5, Iss 6, Pp 673-678 (2021)
Abstract Background and Aim Helicobacter pylori antibody levels in the blood are currently measured using an ELISA. In April 2016, FUJIFILM Wako Pure Chemical Corporation launched the “l‐type Wako Helicobacter pylori antibody J" test, which is ba
Externí odkaz:
https://doaj.org/article/f9bb5aa582ac40caacb0ab9c86d9b656
Autor:
Hiroki Osumi, Eiji Shinozaki, Akira Ooki, Takeru Wakatsuki, Daisaku Kamiimabeppu, Taro Sato, Izuma Nakayama, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
Publikováno v:
Cancer Medicine, Vol 10, Iss 2, Pp 615-625 (2021)
Abstract Background Three vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second‐line chemother
Externí odkaz:
https://doaj.org/article/46dc60a92d2e4e5495daab06b00af794
Publikováno v:
Cancers, Vol 15, Iss 5, p 1473 (2023)
Genotyping of tumor tissues to assess RAS and BRAF V600E mutations enables us to select optimal molecularly targeted therapies when considering treatment strategies for patients with metastatic colorectal cancer. Tissue-based genetic testing is limit
Externí odkaz:
https://doaj.org/article/0e0087228ad14e79b90bcebe392e5440
Autor:
Hiroki Osumi, Atsushi Muroi, Mizuho Sakahara, Hiroshi Kawachi, Takuya Okamoto, Yasuko Natsume, Hitomi Yamanaka, Hiroshi Takano, Daisuke Kusama, Eiji Shinozaki, Akira Ooki, Kensei Yamaguchi, Masashi Ueno, Kengo Takeuchi, Tetsuo Noda, Satoshi Nagayama, Naohiko Koshikawa, Ryoji Yao
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Abstract RAS signaling is a promising target for colorectal cancer (CRC) therapy, and a variety of selective inhibitors have been developed. However, their use has often failed to demonstrate a significant benefit in CRC patients. Here, we used patie
Externí odkaz:
https://doaj.org/article/4a5d7832b5aa4ee2ae61173e8d40b629